OraSure Technologies (OSUR)
Nasdaq Market Closed
OraSure Technologies Inc. is a healthcare diagnostics and sample management company listed under the symbol OSUR. The company develops, manufactures and sells products designed to make medical testing and specimen collection more accessible, including solutions that can be used outside traditional laboratory settings.
OraSure is best known for diagnostic testing platforms and oral fluid collection technologies. Its product portfolio has included tests and collection devices related to infectious disease, sexual health, molecular sampling and public health applications. The company’s technologies support both direct diagnostic testing and the collection, stabilization and transport of biological samples for analysis by laboratories and healthcare organizations.
The business operates at the intersection of diagnostics, population health and healthcare data workflows. By enabling easier sample collection and broader testing access, OraSure serves customers such as healthcare providers, laboratories, government agencies, public health programs, employers and research organizations. Its products can be relevant in settings where rapid testing, at-home collection or large-scale screening programs are needed.
Revenue is primarily generated from the sale of diagnostic products and sample management solutions, with the United States representing its largest market. OraSure’s results can be influenced by testing demand, regulatory approvals, public health funding, product mix and the competitive landscape for diagnostics and laboratory services.
For investors, OSUR represents exposure to a specialized medical technology company focused on practical tools that expand access to testing and sample collection. Its long-term positioning depends on innovation, manufacturing execution, regulatory compliance and the ability to adapt its product portfolio to changing healthcare and public health priorities.
Last updated
- Market Cap
- 275.39M
- P/E
- —
- P/FCF
- —
- P/S
- 2.44
- Enterprise Value
- 98.66M
- Sector
- Health Care
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 220 E FIRST ST, BETHLEHEM, PA, 18015
Is Co-Diagnostics National Security’s Next Diagnostic Pick?
OraSure Technologies Appoints John D. Bertrand to its Board of Directors
Drug Screening Market Trends 2026–2031: Chromatography and Mass Spectrometry Held a 44.77% Share in 2025 Amid Growing Demand for Advanced Testing, Reports Mordor Intelligence
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - Privacy, Digital Access, and Rapid Results Accelerate Adoption
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
Global At-Home Testing Market to Reach USD 11,877.8 Million by 2035 with a CAGR of 4.8%, Driven by Rising Consumer Demand for Self-Diagnostic Tools | Future Market Insights, Inc.
Microbiome Diagnostics Market to hit USD 429.2 million by 2032, says Global Market Insights Inc.
OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th - GlobeNewswire
OraSure Technologies Supports National HIV Testing Day
OraSure Technologies (OSUR) Q1 Earnings Meet Estimates
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
Abbott (ABT) Q4 Earnings Match Estimates
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
Buy These 4 Low-Beta Stocks to Counter Market Volatility
OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company
After Golden Cross, OraSure Technologies (OSUR)'s Technical Outlook is Bright
OraSure to Participate in Upcoming Investor Conferences
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 275.39M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 98.66M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.88
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 2.44
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.58
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.87
- EPS
- -1.09
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -47.88M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -23.96%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -19.8%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 5.46
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 4.77
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 4.01
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 724.75K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 4
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 27.93M | 26.76M | 27.09M | 31.24M | 29.93M |
| Gross profit | 11.8M | 10.97M | 11.77M | 13.16M | 12.3M |
| Operating income | -23.27M | -19.84M | -16.09M | -18.03M | -18.74M |
| EBITDA | -21.01M | -12.86M | -13.71M | -14.88M | -15.97M |
| Net income | -22.38M | -19.29M | -13.71M | -19.69M | -16.04M |
| Basic EPS | -0.32 | -0.27 | -0.19 | -0.26 | -0.21 |
| Diluted EPS | -0.32 | -0.27 | -0.19 | -0.26 | -0.21 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 379.17M | 403.17M | 423.1M | 445.04M | 457.61M |
| Total liabilities | 65.85M | 62.34M | 61.12M | 64.31M | 61.33M |
| Total equity | 313.32M | 340.83M | 361.98M | 380.72M | 396.28M |
| Cash & equivalents | 176.96M | 199.28M | 216.48M | 234.58M | 247.57M |
| Current assets | 240.78M | 261.91M | 283.01M | 301.44M | 313.78M |
| Current liabilities | 44.08M | 39.8M | 40.25M | 42.35M | 25.42M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -13.9M | -9M | -10.07M | -10.22M | -19.73M |
| Investing cash flow | -913K | -4.42M | -821K | -1.94M | 370K |
| Financing cash flow | -6.28M | -5.11M | -5.08M | -5.8M | -953K |
| Change in cash | -22.31M | -17.2M | -18.1M | -12.99M | -20.19M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 3 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| form 4 | Form 4 — Boyd Steven Kyle | View Filing | |
| form 4 | Form 4 — Gagliano Nancy J | View Filing | |
| form 4 | Form 4 — McMahon Robert W. | View Filing | |
| form 4 | Form 4 — Marmora Lelio | View Filing | |
| form 4 | Form 4 — Boyd Steven Kyle | View Filing | |
| form 4 | Form 4 — Bertrand John D. | View Filing | |
| form 4 | Form 4 — Boyd Steven Kyle | View Filing | |
| edgar index | 10-Q — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 8-K — ORASURE TECHNOLOGIES INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | PRE 14A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 8-K — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DEFA14A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DEFA14A — ORASURE TECHNOLOGIES INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 8-K — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DEFA14A — ORASURE TECHNOLOGIES INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ORASURE TECHNOLOGIES INC | View Filing | |
| form 4 | Form 4 — Boyd Steven Kyle | View Filing | |
| form 4 | Form 4 — Boyd Steven Kyle | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| form 4 | Form 4 — EGLINTON MANNER CARRIE | View Filing | |
| form 4 | Form 4 — McGrath Kenneth J | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DFAN14A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DEFA14A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| form 4 | Form 4 — EGLINTON MANNER CARRIE | View Filing | |
| form 4 | Form 4 — McGrath Kenneth J | View Filing | |
| edgar index | 10-K — ORASURE TECHNOLOGIES INC | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — ORASURE TECHNOLOGIES INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| form 4 | Form 4 — EGLINTON MANNER CARRIE | View Filing | |
| form 4 | Form 4 — McGrath Kenneth J | View Filing | |
| form 4 | Form 4 — Anthony Michele Marie | View Filing | |
| form 4 | Form 4 — EGLINTON MANNER CARRIE | View Filing | |
| form 4 | Form 4 — EGLINTON MANNER CARRIE | View Filing | |
| form 4 | Form 4 — EGLINTON MANNER CARRIE | View Filing | |
| form 4 | Form 4 — McGrath Kenneth J | View Filing | |
| form 4 | Form 4 — McGrath Kenneth J | View Filing | |
| form 4 | Form 4 — McGrath Kenneth J | View Filing | |
| form 4 | Form 4 — Anthony Michele Marie | View Filing | |
| form 4 | Form 4 — Anthony Michele Marie | View Filing | |
| form 4 | Form 4 — Anthony Michele Marie | View Filing | |
| edgar index | 8-K — ORASURE TECHNOLOGIES INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DFAN14A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DEFA14A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | 8-K — ORASURE TECHNOLOGIES INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC | View Filing | |
| edgar index | DEFA14A — ORASURE TECHNOLOGIES INC | View Filing | |
| form 4 | Form 4 — Kenny John P. | View Filing | |
| edgar index | 144 — ORASURE TECHNOLOGIES INC | View Filing |